--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ARGX20261218C930
Biological Technology
Argenx Se was established on 25 April 2008 under the laws of the Netherlands as a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid). On May 28, 2014, the company was converted into a public limited liability company (naamloze vennootschap) under the Notarized Conversion Deed and Amendment. The company is a commercial-stage, global, fully integrated biopharmaceutical company developing differentiated therapies for the treatment of serious autoimmune diseases.
